OPK Latest Press Releases

-- November 4, 2026 --

OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results Globe Newswire 4:23 PM

-- October 28, 2026 --

OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026 Globe Newswire 8:52 AM

-- October 27, 2026 --

OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly Globe Newswire 8:00 AM

-- October 15, 2026 --

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health PRNewswire 7:30 AM

-- September 8, 2026 --

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference Globe Newswire 1:55 PM

-- August 13, 2026 --

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests Globe Newswire 9:15 AM

-- August 3, 2026 --

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health Globe Newswire 7:00 AM

-- July 27, 2026 --

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results Globe Newswire 4:05 PM

-- July 23, 2026 --

OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026 Globe Newswire 12:30 PM

-- June 16, 2026 --

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 Globe Newswire 8:33 AM

-- June 15, 2026 --

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026 Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes